Policy Comments
The priority legislative and regulatory issues that the Cancer Policy Institute focuses on are driven by policy pillars that are centered around the values, needs, and preferences of individuals impacted by cancer. We work in conjunction with patients, patient advocacy organizations, medical associations, and other stakeholders to advance policies aimed at improving access to, affordability of, and quality of care across the cancer continuum.
Letter to ICER urging the use of a patient and people with disabilities centered value framework in the 2024 Value Assessment Framework, increasing accessibility and equity.
Public Input Comment to CMS, urging the reversal of the decision to element procedure code S2068 for deep inferior epigastric perforator (DIEP) flap breast reconstruction surgery.
Letter supporting the implementation of the New York Section 1322 State Innovation waiver to expand its Essential Plan to more New Yorkers, reducing the numbers of uninsured individuals, substantially lowering healthcare costs, and improving health equity, while still satisfying federal guardrails protections.
Letter endorsing H.R. 1843 / S. 1001 which would permanently exempt high deductible health plans from the requirement of a deductible for telehealth and other remote care services.
Letter to House and Senate Leadership urging Congress to protect patient access and quality care for Medicare beneficiaries by keeping providers whole in Medicare’s drug price negotiation process and removing them from the middle of this negotiation process.
Letter urging HHS to protect access to care in the Medicaid program by immediately pausing redeterminations in states where individuals are overwhelmingly losing coverage for procedural reasons.
Letter supporting HR 1826 which waive deductibles, copayments, and coinsurances for prostate cancer screenings for those with a family history of prostate cancer, including those with a genetic alteration known to be associated with an increased risk of prostate cancer, or who are African-American.
Letter thanking the Department of Justice for requesting a stay in the ruling of Braidwood v. Becerra which threatens coverage of USPSTF recommended services without cost-sharing requirements.
Comments to CMS regarding implementation of the drug price negotiation provision of the IRA addressing input regarding clinical benefit, unintended consequences of drug price negotiation, and additional efforts to address affordability.
Letter urging members of Congress to protect Medicaid from cuts in program funding in budget negotiations and other legislation.